New combo therapy aims to boost survival in kids with aggressive lymphoma
NCT ID NCT02405676
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding four doses of rituximab to an intensified chemotherapy regimen improves outcomes for children and teens with advanced B-cell non-Hodgkin lymphoma or B-cell acute leukemia. About 200 participants in China will receive the new treatment, and researchers will compare their event-free survival to a previous study. The goal is to find a more effective way to control these aggressive cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rituximab (a targeted antibody) plus chemotherapy drugs (prednisone, vincristine, cyclophosphamide, cytarabine, doxorubicin, ifosfamide, etoposide, methotrexate)
What this could lead to
If successful, this could lead to a more effective treatment regimen for children with advanced B-cell lymphoma or leukemia, improving their chances of staying cancer-free.
What could go wrong
This is a Phase 2/3 trial, so results are not yet confirmed. The stronger chemotherapy may cause more side effects, and the benefit of adding rituximab is still being tested.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Second University Hospital of Sichuan University
Chengdu, Sichuan, China